ATE260254T1 - Omega-cycloalkyl-prostaglandin e2 derivate - Google Patents

Omega-cycloalkyl-prostaglandin e2 derivate

Info

Publication number: ATE260254T1
Authority: AT; Austria
Prior art keywords: prostaglandin; omega; cycloalkyl; derivatives; formula
Prior art date: 1997-12-25

Application number

AT98961522T

Other languages

English (en)

Inventor

Kousuke Tani

Shuichi Ohuchida

Original Assignee

Ono Pharmaceutical Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-12-25

Filing date

1998-12-24

Publication date

2004-03-15

1998-12-24 Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co

2004-03-15 Application granted granted Critical

2004-03-15 Publication of ATE260254T1 publication Critical patent/ATE260254T1/de

Links

208000023275 Autoimmune disease Diseases 0.000 abstract 1
229920000858 Cyclodextrin Polymers 0.000 abstract 1
208000010412 Glaucoma Diseases 0.000 abstract 1
206010067125 Liver injury Diseases 0.000 abstract 1
208000005107 Premature Birth Diseases 0.000 abstract 1
206010036590 Premature baby Diseases 0.000 abstract 1
206010000210 abortion Diseases 0.000 abstract 1
231100000176 abortion Toxicity 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
231100000234 hepatic damage Toxicity 0.000 abstract 1
208000026278 immune system disease Diseases 0.000 abstract 1
230000008818 liver damage Effects 0.000 abstract 1
230000016273 neuron death Effects 0.000 abstract 1
201000001119 neuropathy Diseases 0.000 abstract 1
230000007823 neuropathy Effects 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
210000000056 organ Anatomy 0.000 abstract 1
230000011164 ossification Effects 0.000 abstract 1
208000033808 peripheral neuropathy Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
210000001525 retina Anatomy 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

AT98961522T 1997-12-25 1998-12-24 Omega-cycloalkyl-prostaglandin e2 derivate ATE260254T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP36624497		1997-12-25
PCT/JP1998/005863 WO1999033794A1 (en)	1997-12-25	1998-12-24	φ-CYCLOALKYL-PROSTAGLANDIN E2 DERIVATIVES

Publications (1)

Publication Number	Publication Date
ATE260254T1 true ATE260254T1 (de)	2004-03-15

Family

ID=18486293

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT98961522T ATE260254T1 (de)	1997-12-25	1998-12-24	Omega-cycloalkyl-prostaglandin e2 derivate

Country Status (7)

Country	Link
US (1)	US6262293B1 (de)
EP (1)	EP1042283B1 (de)
KR (1)	KR20010033538A (de)
AT (1)	ATE260254T1 (de)
DE (1)	DE69821987T2 (de)
ES (1)	ES2216336T3 (de)
WO (1)	WO1999033794A1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6235780B1 (en) *	1998-07-21	2001-05-22	Ono Pharmaceutical Co., Ltd.	ω-cycloalkyl-prostaglandin E1 derivatives
CA2364948C (en)	1999-03-05	2011-04-26	Duke University	C16 unsaturated fp-selective prostaglandins analogs
US6894175B1 (en)	1999-08-04	2005-05-17	The Procter & Gamble Company	2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
KR20020067594A (ko) *	2000-01-05	2002-08-22	오노 야꾸힝 고교 가부시키가이샤	5-티아-ω-치환 페닐-프로스타글란딘 Ｅ-알콜, 이들의제조 방법 및 이들을 유효 성분으로서 함유하는 약제
US20020013294A1 (en)	2000-03-31	2002-01-31	Delong Mitchell Anthony	Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en)	2000-03-31	2002-11-21	Delong Michell Anthony	Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020037914A1 (en)	2000-03-31	2002-03-28	Delong Mitchell Anthony	Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
JP2002027998A (ja) *	2000-09-29	2002-01-29	Shionogi & Co Ltd	神経細胞変性調節活性の測定方法
US6586462B2 (en)	2000-10-20	2003-07-01	Allergan, Inc.	ω-Cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
US6376533B1 (en) *	2000-10-20	2002-04-23	Allergan Sales, Inc.	Omega-cycloalkyl 17-heteroaryl prostaglandin E2 analogs as EP2-receptor agonists
AU2003224244A1 (en) *	2002-03-27	2003-10-13	Rosanto Pharmaceuticals Ltd	Improvements in pharmaceutical compositions
JP2006021998A (ja) *	2002-07-18	2006-01-26	Ono Pharmaceut Co Ltd	Ｅｐ２アゴニストを有効成分とする月経困難症治療剤
HUE029417T2 (en)	2002-10-10	2017-02-28	Ono Pharmaceutical Co	Microspheres containing ONO-1301
WO2004073591A2 (en) *	2003-02-24	2004-09-02	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep2 (prostaglandin e2 ep2)
JP4662926B2 (ja)	2003-03-03	2011-03-30	メルクセローノソシエテアノニム	プロスタグランジン作動薬としてのγ−ラクタム誘導体
JP2005511607A (ja) *	2003-07-10	2005-04-28	アラーガン、インコーポレイテッド	ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
EP1654219A2 (de)	2003-07-18	2006-05-10	Applied Research Systems ARS Holding N.V.	Hydrazinderivate als modulatoren des prostaglandinrezeptors
WO2005009468A1 (ja)	2003-07-25	2005-02-03	Ono Pharmaceutical Co., Ltd.	軟骨関連疾患治療剤
EP1806148A4 (de)	2004-10-22	2009-12-02	Ono Pharmaceutical Co	Medizinische zusammensetzung zur inhalation
MY144968A (en) *	2005-04-11	2011-11-30	Xenon Pharmaceuticals Inc	Spiro-oxindole compounds and their uses as therapeutic agents
AR053710A1 (es) *	2005-04-11	2007-05-16	Xenon Pharmaceuticals Inc	Compuestos espiroheterociclicos y sus usos como agentes terapeuticos
JP5040650B2 (ja)	2005-06-03	2012-10-03	小野薬品工業株式会社	神経再生および／または保護剤
EP3205644A1 (de)	2005-12-29	2017-08-16	Celtaxsys Inc.	Diaminderivate als inhibitoren der leukotrien-a4 hydrolase
WO2008046049A1 (en) *	2006-10-12	2008-04-17	Xenon Pharmaceuticals Inc.	Spiro (furo [3, 2-c] pyridine-3-3 ' -indol) -2' (1'h)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
EP2073806B1 (de)	2006-10-12	2012-02-15	Xenon Pharmaceuticals Inc.	Verwendung von spiro-oxindol-verbindungen als therapeutika
HRP20150882T1 (hr) *	2008-10-17	2015-09-25	Xenon Pharmaceuticals Inc.	Spirooksindolski spojevi i njihova upotreba kao terapijska sredstva
WO2010045197A1 (en) *	2008-10-17	2010-04-22	Xenon Pharmaceuticals, Inc.	Spiro-oxindole compounds and their use as therapeutic agents
AR077252A1 (es)	2009-06-29	2011-08-10	Xenon Pharmaceuticals Inc	Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
WO2011008756A1 (en)	2009-07-13	2011-01-20	Irix Pharmaceuticals	Synthesis of prostanoids
PE20170202A1 (es)	2009-10-14	2017-03-24	Xenon Pharmaceuticals Inc	Metodos sinteticos para compuestos espiro-oxoindol
US20110086899A1 (en) *	2009-10-14	2011-04-14	Xenon Pharmaceuticals Inc.	Pharmaceutical compositions for oral administration
US8299068B2 (en) *	2010-01-29	2012-10-30	Allergan, Inc.	Therapeutically active cyclopentanes
RU2596488C2 (ru)	2010-02-26	2016-09-10	Ксенон Фармасьютикалз Инк.	Фармацевтические композиции спиро-оксиндольного соединения для местного введения и их применение в качестве терапевтических агентов
KR20150002794A (ko)	2012-04-12	2015-01-07	제논 파마슈티칼스 인크.	치료제로서 유용한 스파이로-옥시인돌 화합물을 위한 비대칭적 합성
ES2733998T3 (es)	2012-10-29	2019-12-03	Cardio Incorporated	Agente terapéutico específico de enfermedad pulmonar
AU2014240042C1 (en)	2013-03-14	2019-09-05	Celltaxis, Llc	Inhibitors of leukotriene A4 hydrolase
WO2015048736A1 (en)	2013-09-30	2015-04-02	Irix Pharmaceuticals, Inc.	Novel synthesis routes for prostaglandins and prostaglandin intermediates using metathesis
US9968716B2 (en)	2013-10-15	2018-05-15	Ono Pharmaceutical Co., Ltd.	Drug-eluting stent graft
AR103636A1 (es)	2015-02-05	2017-05-24	Teva Pharmaceuticals Int Gmbh	Métodos de tratamiento de neuralgia postherpética con una formulación tópica de un compuesto de espiro-oxindol
ES2837399T3 (es) *	2015-07-23	2021-06-30	Ono Pharmaceutical Co	Derivados de ácido 2-(octahidrociclopenta(b)piran-2-il)1,3-tiazol-4-carboxílico y compuestos relacionados como agonistas de EP2 con actividad reductora de la presión intraocular
WO2017218920A1 (en)	2016-06-16	2017-12-21	Teva Pharmaceuticals International Gmbh	Asymmetric synthesis of funapide
WO2018107158A1 (en)	2016-12-09	2018-06-14	Celtaxsys, Inc.	Monamine and monoamine derivatives as inhibitors of leukotriene a4 hydrolase
CA3045887A1 (en)	2016-12-09	2018-06-14	Celtaxsys, Inc.	Pendant amines and derivatives as inhibitors of leukotriene a4 hydrolase
US10202362B2 (en)	2016-12-09	2019-02-12	Celtaxsys, Inc.	Inhibitors of leukotriene A4 hydrolase
JPWO2023127855A1 (de) *	2021-12-28	2023-07-06

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4275224A (en)	1978-02-23	1981-06-23	Miles Laboratories, Inc.	15-Deoxy-16-hydroxy prostaglandins
US4132738A (en)	1978-02-23	1979-01-02	Miles Laboratories, Inc.	Preparation of 15-deoxy-16-hydroxyprostaglandins

1998
- 1998-12-24 WO PCT/JP1998/005863 patent/WO1999033794A1/en not_active Ceased
- 1998-12-24 KR KR1020007007046A patent/KR20010033538A/ko not_active Ceased
- 1998-12-24 AT AT98961522T patent/ATE260254T1/de not_active IP Right Cessation
- 1998-12-24 ES ES98961522T patent/ES2216336T3/es not_active Expired - Lifetime
- 1998-12-24 EP EP98961522A patent/EP1042283B1/de not_active Expired - Lifetime
- 1998-12-24 DE DE69821987T patent/DE69821987T2/de not_active Expired - Fee Related
- 1998-12-24 US US09/582,348 patent/US6262293B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2216336T3 (es)	2004-10-16
US6262293B1 (en)	2001-07-17
EP1042283A1 (de)	2000-10-11
WO1999033794A1 (en)	1999-07-08
DE69821987T2 (de)	2004-12-16
KR20010033538A (ko)	2001-04-25
EP1042283B1 (de)	2004-02-25
DE69821987D1 (de)	2004-04-01

Legal Events

Date	Code	Title	Description
2004-08-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69821987D1 (de)	2004-04-01	Omega-cycloalkyl-prostaglandin e2 derivate
ATE218544T1 (de)	2002-06-15	Omega-zykloalkyl-prostaglandin e1 derivate
EP0860430A3 (de)	1999-06-23	Omega-Zykloalkyl-Prostaglandin E2 Derivate
BR0010704A (pt)	2002-02-05	Composições e métodos de anti-náusea
CA2413190A1 (en)	2002-01-10	Methods for treating rheumatic diseases using a soluble ctla4 molecule
BG106867A (en)	2003-02-28	Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory autoimmune and respiratory diseases
LU91928I2 (fr)	2012-03-09	Ipilimumab et ses dérivés pharmaceutiquement acceptables (YERVOY®)
ATE496620T1 (de)	2011-02-15	1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
TR200200843T2 (tr)	2002-07-22	İşemi'nin Tedavisi için olan bileşikler
BR9811099A (pt)	2002-05-14	Inibidores de urocinase
ATE248837T1 (de)	2003-09-15	Chinuclidin-acrylamide
AU2002314914A1 (en)	2002-12-16	Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
BR0007589A (pt)	2002-10-15	Inibidores da proliferação de células
WO2003063787A3 (en)	2004-01-22	Non-steroidal analogs of 2-methoxyestradiol
TR200001452T2 (tr)	2004-12-21	Bifenilamidin türevleri.
NO20050666L (no)	2005-03-11	2,7-substituerte indoler og deres anvendelse som 5-HT6 modulatorer
WO2003072558A3 (en)	2003-12-24	Arylsulfone derivatives
AU2004216182A1 (en)	2004-09-10	Selective non-steroidal glucocorticoid receptor modulators
TR199902257T2 (xx)	1999-12-21	Tetrahidropirido bile�ikleri
NO20014240D0 (no)	2001-08-31	C16-umettede FP-selektive prostaglandinanaloger
DK1109560T3 (da)	2003-11-03	Som AICARFT-inhibitorer anvendelige forbindelser
DE60141641D1 (de)	2010-05-06	Substituierte (e)-styrylbenzylsulfone zur behandlung proliferativer erkrankungen
EP1121932A4 (de)	2001-12-19	Heilmittel für augenerkrankungen
WO2000058328A3 (de)	2001-04-26	Avermectinderivate
BG106078A (en)	2002-05-31	Thio-oxindole derivatives